Develops medicines for patients suffering from Alzheimer's disease and other neurological disorders.
Develops medicines for patients suffering from Alzheimer's disease and other neurological disorders.
Alzheon is a privately held clinical stage, biotechnology company based in Framingham, Massachusetts. It focuses on developing medications by directly addressing the underlying pathology of neurodegenerative disorders.
Founded in 2013, the company's lead product candidate is ALZ-801, a patented, orally administered prodrug of tramiprosate that is designed to inhibit amyloid oligomer formation, a key driver of Alzheimer's disease. The product is intended to focus on patients with mild Alzheimer's with the APOE4 genotype. It has been granted Fast Track Designation by the FDA in October 2017. Phase 3 clinical trials are planned for 2019. Alzheon's product pipeline also has ALZ-1903, a pre-clinical candidate with the potential to inhibit amyloid misfolding.
In April 2018, the company planned an $80 million IPO, but soon withdrew the offer. It re-announced later in August a $40 million IPO. However, that too was withdrawn in January 2019.
Aidan Power
VP, Program and Portfolio Management
John Hey
Chief Scientific Officer
Kenneth Mace
VP, Finance
Martin Tolar
Founder, President & CEO
Susan Abushakra
Chief Medical Officer
Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease, Further Supporting Precision Medicine Approach and Planned Confirmatory Clinical Trial with ALZ-801
Web
What Happened? Alzheon Leaves IPO on the Table for the Second Time | BioSpace
Alex Keown
Web